Skip to main content
Caplight Logo









Artus Therapeutics

Artus Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://artustx.com/

Last Round

Grant

Jul 1, 2021

Total Funding Raised

$501,189

Company Overview

Artus Therapeutics is a biotechnology company that develops small-molecule therapeutics for inflammatory and metabolic diseases by targeting gut barrier dysfunction.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverysmall molecule therapeuticspreclinical developmentsmall molecule inhibitorsbiotech startupdrug pipelinemedicinal chemistrytherapeutic interventionbiotech licensingpharma partnershipearly-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Artus Therapeutics Comparables

Compare Artus Therapeutics with similar companies based on industry and business-model similarity.

Artus Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Oncostellae
84%
Orphagen Pharmaceuticals
80%
Piton Therapeutics
79%

Artus Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJul 1, 2021
SeedAug 1, 2019

Key People

Founding team and executive leadership

Sakthi Jagadeesan

Co-Founder and CEO

Founding Team

Artus Therapeutics Investors

Notable investors and investment history

Artus Therapeutics investors
InvestorRounds
National Institutes of Health (NIH)Grant

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 3, 2025

    Monthly visitors grew 60% MoM, reaching 1.6K.

  • Jul 1, 2021

    $501K grant awarded by the National Institutes of Health.

Artus Therapeutics Filings

Explore SEC and related filing metadata, where available.

Artus Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Artus Therapeutics's valuation, stock price, and market status.

Is Artus Therapeutics a public or private company?

Artus Therapeutics is a private company.

What is the current stock price of Artus Therapeutics?

Artus Therapeutics is a private company with no public stock price. Caplight tracks Artus Therapeutics's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is Artus Therapeutics worth (valuation)?

Valuation information for Artus Therapeutics is not publicly available.

Can I buy Artus Therapeutics stock?

Artus Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Artus Therapeutics's last funding round?

Artus Therapeutics's most recent funding round was Grant on July 1, 2021.

Who are the main investors in Artus Therapeutics?

Key investors in Artus Therapeutics include National Institutes of Health (NIH).

Will Artus Therapeutics IPO soon?

No public IPO plans have been announced for Artus Therapeutics.

How can I track Artus Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Artus Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range1
Year Founded2019
Last FundingJul 1, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?